The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre

被引:28
作者
Singal, A. G.
Rakoski, M. O.
Salgia, R.
Pelletier, S. [2 ]
Welling, T. H. [2 ]
Fontana, R. J.
Lok, A. S.
Marrero, J. A. [1 ]
机构
[1] Univ Michigan, Div Gastroenterol, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Div Gastroenterol, Dept Surg, Ann Arbor, MI 48109 USA
关键词
HILAR CHOLANGIOCARCINOMA; SURGICAL-MANAGEMENT; KLATSKIN-TUMORS; UNITED-STATES; RISK-FACTORS; IMPACT; CLASSIFICATION; RESECTION;
D O I
10.1111/j.1365-2036.2009.04218.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The incidence of cholangiocarcinoma is rising. Accurate predictors of survival at diagnosis are not well defined. Aim To clarify the clinical presentation and prognostic factors of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma in a contemporary cohort of patients. Methods Records for consecutive patients at the University of Michigan hospital diagnosed with cholangiocarcinoma between January 2003 and April 2008 were reviewed. Results In all, 136 patients had cholangiocarcinoma (79 intra- and 57 extrahepatic cholangiocarcinoma). Median survival was 27.3 months-25.8 months for intrahepatic cholangiocarcinoma and 30.3 months for extrahepatic cholangiocarcinoma. Independent predictors of mortality at presentation on multivariate analysis were elevated bilirubin level (HR 1.04, 95% CI 1.01-1.07), CA 19-9 levels >100 U/mL (HR 1.90, 95% CI 1.17-3.08) and stage of disease (HR 1.51, 95% CI 1.16-1.96). After adjusting for baseline prognostic factors, surgical therapy was associated with improved survival (HR 0.48; 95% CI 0.26-0.88). There were no significant differences regarding clinical presentation, disease stage (P = 0.98), and survival (P = 0.51) between intra- and extrahepatic cholangiocarcinoma. Conclusions Survival for cholangiocarcinoma remains poor with no significant difference in outcomes between intra- and extrahepatic cholangiocarcinoma. Stage of disease, bilirubin level and CA 19-9 level are important prognostic factors at presentation. Surgical therapy provides similar efficacy for both tumours when adjusted for other prognostic variables.
引用
收藏
页码:625 / 633
页数:9
相关论文
共 26 条
[1]   Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: Prognostic factors and longterm outcomes [J].
Baton, Olivier ;
Azoulay, Daniel ;
Adam, Delvart V. Rene ;
Castaing, Denis .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 204 (02) :250-260
[2]   Risk factors for cholangiocarcinoma [J].
Ben-Menachem, Tamir .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2007, 19 (08) :615-617
[3]   Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents [J].
Cheng, JLS ;
Bruno, MJ ;
Bergman, JJ ;
Rauws, EA ;
Tytgat, GN ;
Huibregtse, K .
GASTROINTESTINAL ENDOSCOPY, 2002, 56 (01) :33-39
[4]   Cholangiocarcinoma: Current concepts and insights [J].
Gores, GJ .
HEPATOLOGY, 2003, 37 (05) :961-969
[5]  
Hanazaki K, 2002, HEPATO-GASTROENTEROL, V49, P311
[6]   Surgical resection of hilar cholangiocarcinoma: Analysis of survival and postoperative complications [J].
Hasegawa, Suguru ;
Ikai, Iwao ;
Fujii, Hideaki ;
Hatano, Etsuro ;
Shimahara, Yasuyuki .
WORLD JOURNAL OF SURGERY, 2007, 31 (06) :1256-1263
[7]   Surgical management of hilar cholangiocarcinoma [J].
Hemming, AW ;
Reed, AI ;
Fujita, S ;
Foley, DP ;
Howard, RJ .
ANNALS OF SURGERY, 2005, 241 (05) :693-702
[8]  
Heron DE, 2003, AM J CLIN ONCOL-CANC, V26, P422
[9]   Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma [J].
Jarnagin, WR ;
Fong, Y ;
DeMatteo, RP ;
Gonen, M ;
Burke, EC ;
Bodniewicz, J ;
Youssef, M ;
Klimstra, D ;
Blumgart, LH .
ANNALS OF SURGERY, 2001, 234 (04) :507-517
[10]  
KHAN SA, 2002, GUT S6, V51, P9